turoctocog alfa
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Factor VIII (FVIII) is indicated for the prevention or treatment of bleeding in patients with hemophilia A. FVIII product…
Essentials Chromogenic assays may be less variable than one‐stage clot assays for measuring modified factor VIII. Chromogenic…
Turoctocog alfa (NovoEight®) is a human recombinant coagulation factor VIII (rFVIII) for the treatment of patients with…
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prevention and treatment of…
Turoctocog alfa (NovoEight®) is a new recombinant factor VIII (rFVIII) with a truncated B domain and a high degree of tyrosine…
Haemophilia and its treatment interfere with patients' life, so health‐related quality of life (HRQoL) should be assessed when…
Turoctocog alfa (NovoEight®) is a recombinant factor VIII (rFVIII) with a truncated B‐domain made from the sequence coding for 10…
Hemophilia A (HA) represents one of the most common genetic bleeding disorders worldwide and results from a deficiency in factor…
Recombinant factor VIII (rFVIII) products provide a safe and efficacious replacement therapy for prophylaxis and treatment of…